Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31343356 | 0.96 | OPRK1 (0.60) | OPRK1OPRM1OPRD1NPY1RNPY2R | |
| SCHEMBL29798006 | 0.96 | OPRK1 (0.61) | OPRK1OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL31134058 | 0.94 | NPY4R (0.61) | OPRK1NPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL29679986 | 0.94 | NPY4R (0.62) | OPRK1OPRM1NPY1RNPY2RNPY4R | |
| SCHEMBL30799335 | 0.94 | MMP2 (0.55) | OPRK1OPRM1OPRD1NPY1RNPY2R | |
| SCHEMBL30799661 | 0.93 | OPRK1 (0.60) | OPRK1OPRM1OPRD1NPY1RNPY2R | |
| SCHEMBL30880418 | 0.92 | OPRK1 (0.57) | OPRK1OPRM1OPRD1NPY1RNPY2R | |
| SCHEMBL31181190 | 0.92 | OPRK1 (0.57) | OPRK1OPRM1OPRD1NPY1RNPY2R | |
| SCHEMBL31554972 | 0.92 | MMP2 (0.56) | OPRK1OPRM1OPRD1NPY1RNPY2R | |
| SCHEMBL30497073 | 0.92 | MMP2 (0.56) | OPRK1OPRM1OPRD1NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | OPRK1 3407/4885OPRM1 4382/4885OPRD1 4412/4885 |
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | OPRK1 3434/4885OPRM1 4418/4885OPRD1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.